Terms ending in 2039
Every in-force patent on CureVac AG's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,747,451 | RNA Encoding an Antibody In force · High confidence | CureVac SE | In force | High confidence | |
| US 12,097,253 | RSV RNA Molecules and Compositions for Vaccination In force · Medium confidence | CureVac SE | In force | Medium confidence | |
| US 12,350,330 | RSV RNA Molecules and Compositions for Vaccination In force · Medium confidence | CureVac SE | In force | Medium confidence | |
| US 11,931,406 | Flavivirus Vaccine In force · High confidence | Sanofi R&D Vaccins | In force | High confidence | |
| US 11,478,552 | Hybrid Carriers for Nucleic Acid Cargo In force · Medium confidence | Curevac SE | In force | Medium confidence | |
| US 12,508,308 | Influenza Mrna Vaccines In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,596,699 | RNA Encoding an Antibody In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,684,665 | Method for Producing RNA Molecule Compositions In force · High confidence | Curevac SE | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by CureVac AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.